Protein A, G and L Resins

Global Protein A, G and L Resins Market to Reach US$875.0 Million by 2030

The global market for Protein A, G and L Resins estimated at US$792.0 Million in the year 2024, is expected to reach US$875.0 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Protein G Resin, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$490.2 Million by the end of the analysis period. Growth in the Protein L Resin segment is estimated at 1.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$215.8 Million While China is Forecast to Grow at 3.3% CAGR

The Protein A, G and L Resins market in the U.S. is estimated at US$215.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.2 Million by the year 2030 trailing a CAGR of 3.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Protein A, G, And L Resins Market - Key Trends & Drivers Summarized
Why Are Protein A, G, and L Resins Gaining Strategic Importance in Biopharmaceutical Purification?
Protein A, G, and L resins are critical affinity chromatography media used in the downstream purification of monoclonal antibodies (mAbs), recombinant proteins, and immunoglobulins. Their high selectivity for specific immunoglobulin (Ig) domains makes them essential in ensuring product purity, yield, and efficiency in bioprocessing workflows. Protein A resins, derived from Staphylococcus aureus, have become the industry standard for capturing IgG antibodies due to their strong binding affinity for the Fc region. Protein G and Protein L resins complement this capability by enabling purification of antibody fragments and Ig subtypes that Protein A does not efficiently bind.

As the biopharmaceutical industry expands its focus beyond mAbs to include bispecific antibodies, antibody fragments, and fusion proteins, the need for versatile and subtype-specific resins has intensified. Protein G resins bind a broader range of IgG subclasses across various species, while Protein L resins uniquely target kappa light chains, enabling purification of Fab fragments, scFv, and other light-chain-containing constructs. The diversity of these affinity ligands allows manufacturers to fine-tune purification strategies across preclinical, clinical, and commercial-scale production pipelines-enhancing throughput, compliance, and scalability.

Which End-Use Segments and Bioprocessing Applications Are Driving Adoption of Affinity Resins?
The primary end-user segment for Protein A, G, and L resins is the biopharmaceutical manufacturing industry, particularly in monoclonal antibody production for therapeutic and diagnostic applications. During large-scale manufacturing, Protein A chromatography serves as the first capture step in downstream processing, ensuring removal of process-related impurities and concentration of the target antibody. This step is foundational for achieving regulatory-grade purity and lot consistency. With mAbs constituting over 60% of current biologic drug approvals, the demand for Protein A resins continues to surge in both originator and biosimilar pipelines.

Protein G and L resins are increasingly utilized in research laboratories, contract development and manufacturing organizations (CDMOs), and diagnostic reagent companies. In particular, Protein G is valuable for purifying polyclonal IgG from animal models used in preclinical studies. Protein L resins, which lack Fc-binding properties, are used for isolating antibody fragments from bacterial or mammalian expression systems-especially in next-generation antibody therapies like CAR-T, nanobodies, and ADCs. These resins are also important for immunoprecipitation, immunoassay development, and analytical protein quantification in quality control labs.

How Are Resin Technologies, Binding Capacities, and Reusability Advancing Market Offerings?
Innovations in resin matrix materials, ligand engineering, and elution conditions are enhancing the performance of affinity resins across parameters such as dynamic binding capacity (DBC), chemical stability, and cycle life. Protein A ligands are being genetically modified or chemically engineered to reduce leaching, lower non-specific binding, and improve alkaline stability-enabling reuse across multiple purification cycles without significant loss in functionality. Manufacturers like Cytiva (MabSelect), Repligen (Natrix), Purolite, and Tosoh Bioscience are offering next-generation Protein A resins with DBC exceeding 50 mg/mL and caustic resistance suitable for 100+ cycles.

Disposable column formats and membrane-based affinity chromatography platforms are also gaining traction, particularly in single-use bioprocessing. These solutions reduce cleaning validation burdens, minimize cross-contamination, and support continuous manufacturing models. Additionally, Protein G and L resins are available in multiple bead sizes and formats (agarose, polymethacrylate, synthetic polymers), allowing compatibility with high-pressure liquid chromatography (HPLC) and fast protein liquid chromatography (FPLC) systems. Some formulations now integrate multi-modal ligands to improve selectivity for antibody-drug conjugates and complex fusion proteins, reflecting the shift toward tailored purification workflows.

What Factors Are Driving the Growth of the Global Protein A, G, and L Resins Market?
The growth in the global Protein A, G, and L resins market is driven by the increasing number of antibody-based therapeutics, rising demand for biosimilars, and expansion of CDMO capacities worldwide. As mAbs, antibody fragments, and novel biologics dominate the drug development pipeline, downstream purification has emerged as a bottleneck-placing pressure on manufacturers to adopt high-efficiency resins with minimal leaching and high throughput. Protein A resins remain irreplaceable in most IgG purification protocols, while Protein G and L address growing needs in research and advanced therapy platforms.

Further, the rise in personalized medicine and cell & gene therapy is boosting small-batch and flexible manufacturing formats, which benefit from scalable, reusable, and single-use resin solutions. Continuous bioprocessing, facilitated by high-capacity resins, is gaining favor for its operational efficiency and reduced footprint. Increasing regulatory scrutiny around product purity and resin extractables is pushing vendors to develop more robust and chemically inert matrices, supported by detailed validation data and GMP compliance.

Major market participants include Cytiva (Danaher), Thermo Fisher Scientific, Merck KGaA, Repligen, Purolite (Ecolab), Tosoh Corporation, Bio-Rad, and Takara Bio. These companies are investing in resin innovation, ligand development, and expanded manufacturing footprints to serve growing biologics hubs in Asia-Pacific, North America, and Europe. With continued biopharma investment in antibody modalities and purification optimization, the Protein A, G, and L resins market is positioned for sustained, high-value growth.

SCOPE OF STUDY:

The report analyzes the Protein A, G and L Resins market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Protein G Resin, Protein L Resin, Protein A Resin); Application (Pharmaceuticals Application, Research Labs Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Abcam plc
• Agarose Bead Technologies
• Agilent Technologies, Inc.
• Avantor, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare (Cytiva)
• EMD Millipore (Merck KGaA)
• GenScript Biotech Corporation
• JSR Life Sciences Corporation
• Kaneka Corporation
• Novasep Holding SAS
• Pall Corporation (Danaher)
• PerkinElmer, Inc.
• Prometic Life Sciences Inc.
• Purolite Life Sciences (Ecolab)
• Repligen Corporation
• Sartorius Stedim Biotech S.A.
• Thermo Fisher Scientific Inc.
• Tosoh Bioscience LLC
• W. R. Grace & Co.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more